Amgen Announces Positive Topline Phase 3 Results For Subcutaneous Tepezza In Adults Living With Moderate-to-severe Active Thyroid Eye Disease
This image was generated by AI and may not depict real events.
Amgen has announced positive results from a Phase 3 trial of TEPEZZA for the treatment of moderate-to-severe active Thyroid Eye Disease. The trial showed a statistically significant and clinically meaningful 77% proptosis response rate during the 24-week placebo-controlled period.
Amgen announced positive results from a Phase 3 trial of TEPEZZA for Thyroid Eye Disease. The trial met its primary endpoint, showing a 77% proptosis response rate. The mean proptosis reduction was -3.17 mm at week 24. The trial also showed improvements in overall responder rate and diplopia response rate. TEPEZZA is the first and only medicine approved for the treatment of Thyroid Eye Disease. The results will be presented at an upcoming medical congress.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.